NCT02283190View on ClinicalTrials.gov

1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

September 30, 2017

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Erwinase

Six doses of Erwinase, given Monday-Wednesday-Friday for 2 weeks. Dosage levels to be used are: 20,000 IU/ m2 /day, 25,000 IU/ m2 /day, 30,000 IU/ m2 /day.

Trial Locations (1)

21201

University of Maryland Greenebaum Cancer Center, Baltimore

All Listed Sponsors
lead

Ashkan Emadi

OTHER

NCT02283190 - 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter